Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gerardi CS"'
Autor:
Matassov D; Auro Vaccines LLC, Pearl River, NY 10965, USA., DeWald LE; Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA., Hamm S; Auro Vaccines LLC, Pearl River, NY 10965, USA., Nowak RM; Auro Vaccines LLC, Pearl River, NY 10965, USA., Gerardi CS; Auro Vaccines LLC, Pearl River, NY 10965, USA., Latham TE; Auro Vaccines LLC, Pearl River, NY 10965, USA., Xu R; Auro Vaccines LLC, Pearl River, NY 10965, USA., Luckay A; Auro Vaccines LLC, Pearl River, NY 10965, USA., Chen T; Auro Vaccines LLC, Pearl River, NY 10965, USA., Tremblay M; Auro Vaccines LLC, Pearl River, NY 10965, USA., Shearer J; Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA., Wynn M; Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA., Eldridge JH; Auro Vaccines LLC, Pearl River, NY 10965, USA., Warfield K; Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA., Spurgers K; Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA.
Publikováno v:
Vaccines [Vaccines (Basel)] 2024 Jul 30; Vol. 12 (8). Date of Electronic Publication: 2024 Jul 30.
Autor:
Clarke DK; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA. Electronic address: dclarke@profectusbiosciences.com., Xu R; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA., Matassov D; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Latham TE; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Ota-Setlik A; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA., Gerardi CS; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Luckay A; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA., Witko SE; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Hermida L; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Higgins T; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Tremblay M; Department of Quality Assurance, Profectus BioSciences, Pearl River, NY, USA., Sciotto-Brown S; Department of Regulatory Affairs, Profectus BioSciences, Pearl River, NY, USA., Chen T; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA., Egan MA; Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA., Rusnak JM; Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA., Ward LA; Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical, Fort Detrick, MD, USA., Eldridge JH; Department of Virology and Vaccine Development, Profectus BioSciences, Pearl River, NY, USA; Department of Immunology, Profectus BioSciences, Pearl River, NY, USA.
Publikováno v:
The Lancet. Infectious diseases [Lancet Infect Dis] 2020 Apr; Vol. 20 (4), pp. 455-466. Date of Electronic Publication: 2020 Jan 14.
Autor:
Woolsey C; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Jankeel A; Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, Irvine, CA, 92697, USA., Matassov D; Department of Virology and Vaccine Vectors, Profectus BioSciences Inc., Pearl River, NY, 10965, USA., Geisbert JB; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Agans KN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Borisevich V; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Cross RW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Deer DJ; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Fenton KA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Latham TE; Department of Virology and Vaccine Vectors, Profectus BioSciences Inc., Pearl River, NY, 10965, USA., Gerardi CS; Department of Virology and Vaccine Vectors, Profectus BioSciences Inc., Pearl River, NY, 10965, USA., Mire CE; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA., Eldridge JH; Department of Virology and Vaccine Vectors, Profectus BioSciences Inc., Pearl River, NY, 10965, USA.; Department of Immunology, Profectus BioSciences Inc., Pearl River, NY, 10965, USA., Messaoudi I; Department of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, Irvine, CA, 92697, USA., Geisbert TW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, 77555, USA. twgeisbe@utmb.edu.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, 77555, USA. twgeisbe@utmb.edu.
Publikováno v:
Scientific reports [Sci Rep] 2020 Feb 20; Vol. 10 (1), pp. 3071. Date of Electronic Publication: 2020 Feb 20.
Autor:
Cross RW; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Xu R; Department of Immunology., Matassov D; Department of Viral Vaccine Development, and., Hamm S; Department of Viral Vaccine Discovery, Profectus BioSciences Inc., Pearl River, New York, USA., Latham TE; Department of Viral Vaccine Development, and., Gerardi CS; Department of Viral Vaccine Development, and., Nowak RM; Department of Viral Vaccine Discovery, Profectus BioSciences Inc., Pearl River, New York, USA., Geisbert JB; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Ota-Setlik A; Department of Immunology., Agans KN; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Luckay A; Department of Immunology., Witko SE; Department of Viral Vaccine Development, and., Soukieh L; Department of Immunology., Deer DJ; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Mire CE; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Feldmann H; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Hamilton, Montana, USA., Happi C; Department of Biological Sciences and African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Edo, Nigeria., Fenton KA; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA., Eldridge JH; Department of Immunology.; Department of Viral Vaccine Development, and.; Department of Viral Vaccine Discovery, Profectus BioSciences Inc., Pearl River, New York, USA., Geisbert TW; Galveston National Laboratory and.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2020 Jan 02; Vol. 130 (1), pp. 539-551.